PSNL Stock — Personalis, Inc.

Personalis, Inc. (PSNL)

Updated October 16, 2026.

PSNL is a Stock. Total return is -45.1% over the past 7.3 years, 232.9 points behind SPY at 187.8%.

Personalis, Inc. develops and sells advanced cancer genomic tests and services, including liquid biopsy tests for detecting minimal residual disease and tissue-based sequencing services that analyze tumors and their microenvironments. The company serves pharmaceutical companies, diagnostics firms, physicians, and cancer patients with tools for therapy selection, clinical trial identification, biomarker discovery, and cancer monitoring. The company does not currently have an established distribution schedule.

PSNL performance versus SPY

Price and return data through 2026-10-16.

Total return is -45.1% over the past 7.3 years, 232.9 points behind SPY at 187.8%. Over the past year its total return — price change plus distributions reinvested — is 52.2%. Its deepest 1-year drawdown was 55.2%.

PSNL key facts

Asset type

Stock

Asset class

Equity

Inception date

06/20/2019

Distribution frequency

None

Last close

$15.65 (as of 2026-10-16)

Market cap

$1,671,417,997

Average volume

3304766.0

Beta

2.322

Payout ratio

0.0%

EPS

$-1.09

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PSNL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 55.2%.

Who may consider PSNL — and who may not

It is a weaker fit for investors who need monthly cash flow (PSNL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PSNL

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions